Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS1317 in MSI-H/dMMR Advanced Solid Tumors
NCT07552376Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of QLS1317 in solid tumor, sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 25 days, Maximum Tolerated Dose at 1 year and 2 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
QLS1317
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07552376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552376.